TrialClinical cancer research : an official journal of the American Association for Cancer Research2017

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR

Maura N Dickler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.